664993-18-4

Upstream product

• 85106-57-6 C₈H₈N₃OS₂^(1-)*K⁽¹⁺⁾ 
• 5351-17-7 4-aminobenzohydrazide 
• 94-09-7 p-aminoethylbenzoate 
• 75-15-0 carbon disulfide 

Downstream Products

• 1608151-02-5 N-{4-[5-(benzylsulfanyl)-1,3,4-thiadiazol-2-yl]phenyl}-1,4-benzodioxane-2-carboxamide 
• 1608151-10-5 N-{4-[5-(benzylsulfanyl)-1,3,4-thiadiazol-2-yl]phenyl}benzamide 
• 1608151-11-6 N-{4-[5-(benzylsulfanyl)-1,3,4-thiadiazol-2-yl]phenyl}-3-bromobenzamide 
• 1608151-05-8 N-(4-{5-[(1,4-benzodioxan-2-yl)methylsulfanyl]-1,3,4-thiadiazol-2-yl}phenyl)benzamide 

Relevant academic research and scientific papers

Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach

Imiquimod (1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine) is efficacious in topical therapy for certain types of skin cancers. Structurally similar EAPB0203 (N-methyl-1-(2-phenethyl)imidazo[1,2-a]quinoxalin-4-amine) has been shown higher in vitro potency than imiquimod. Besides, triazole, oxadiazole, and thiadiazole rings are privileged building blocks in drug design. A series of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole and [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-thiadiazole derivatives were therefore synthesized by incorporation of these rings into the structure of EAPB0203 and assessed their antiproliferative effects against various cancer cell lines. The 1,3,4-oxadiazole derivatives demonstrated the superior effectiveness compared to imiquimod and EAPB0203. Our findings highlight the excellent potential of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as anticancer agents.

Synthesis and biological evaluation of novel disulfides incorporating 1,3,4-thiadiazole scaffold as promising antitumor agents

In the present study, fourteen 2,5-disubstituted 1,3,4-thiadiazole derivatives containing disulfide group were prepared. The resulting compounds 7a–7n were identified by IR, NMR, MS, and elemental analysis. Their antiproliferative properties in vitro were studied employing standard CCK-8 assay against SMMC-7721, MCF-7, and A549 lines. Bioassay indicated that some compounds showed stronger antitumor effects than reference drugs PX-12 and 5-fluorouracil. Among these screened compounds, compound 7h showed excellent biological activities in inhibiting SMMC-7721 cell proliferation with IC50 at 1.93 ± 0.08 μM. Compounds 7k and 7i manifested highly effective growth inhibitory activity versus MCF-7 cells, with IC50 at 3.04 ± 0.09 and 3.54 ± 0.17 μM, respectively. For A549 cells, compound 7m was found to have the highest antitumor potency with IC50 at 3.67 ± 0.13 μM.

Synthesis of new biheterocycles containing a 1,4-benzodioxane fragment

The reaction of 1,4-benzodioxane-2-carbonyl chloride with 5-(4-aminophenyl)-1,3,4-oxa- and -thiadiazole-2-thiols afforded new biheterocyclic compounds which were converted into the corresponding S-benzyl derivatives by treatment with benzyl chloride. 5-(4